Overview

Extension Study Evaluating Etanercept in Ankylosing Spondylitis

Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the health care resource utilization and work status of patients with ankylosing spondylitis undergoing treatment with etanercept by comparing study evaluations with the baseline evaluations in the ASCEND (0881A3-402)(NCT00247962) study.
Phase:
Phase 4
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Etanercept